Nymox Pharmaceutical

Historical price data

Nymox Pharmaceutical is a decades-old, publicly traded biotech with a mission to revolutionize the treatment of urological disorders, primarily BPH. Its core achievement is the development of fexapotide triflutate, a novel injectable oligopeptide that has completed large Phase 3 trials and demonstrated durable symptom relief and a reduction in surgical interventions in long-term studies. The company's strategy is to advance this single asset through regulatory approval, leveraging a lean, virtual operational model to manage resources while targeting a massive, aging global population in need of better BPH therapies.

A proprietary synthetic oligopeptide (fexapotide triflutate) platform designed for targeted intraprostatic injection, inducing localized apoptosis of hyperplastic or cancerous prostate cells to achieve durable therapeutic effects.

Nymox competes in the crowded BPH market against cheap, daily oral generics (alpha-blockers, 5ARIs) and, more directly, against established in-office minimally invasive procedures like UroLift and Rezūm. Its differentiation lies in being a pharmacologic agent with surgical-like durability, but it lacks the commercial scale and physician adoption of its competitors.